Four markets, one distribution partner, and a drug that earned U.S. approval less than 18 months ago: BridgeBio’s move to plant Attruby (acoramidis) across Asia Pacific through DKSH reveals a company unwilling to let regulatory geography slow its commercial clock. The partnership covers Australia, Singapore, South Korea, and Taiwan, with DKSH absorbing the full commercialization burden, from regulatory affairs submissions to launch execution and distribution infrastructure. That is a deliberate outsourcing of complexity in markets where building a proprietary commercial presence would consume years and capital that a mid-size biotech cannot spare while simultaneously managing U.S. market development.
The strategic logic favors DKSH as much as BridgeBio. DKSH Healthcare generated CHF 5.8 billion in net sales in 2025 across roughly 7,580 specialists, but its portfolio skews heavily toward established pharmaceuticals and consumer health products. Anchoring a new chapter of growth around a biotech asset with a compelling Phase 3 dataset is a repositioning signal. The ATTRibute-CM Phase 3 trial showed acoramidis produced a statistically significant treatment effect on a hierarchical primary endpoint including all-cause mortality and cardiovascular-related hospitalization at 30 months, the kind of outcome data that opens reimbursement conversations rather than prolonging them. DKSH’s ability to run those conversations across four distinct payer and regulatory systems simultaneously is precisely what makes it useful here.
The commercial risk is real, though. Acoramidis is not yet approved in any of the four covered markets, and the announcement is explicit that commercialization is contingent on local regulatory clearances. That makes the timeline genuinely uncertain. ATTR-CM is a condition disproportionately affecting older men, and prevalence data from Australia shows the disease skews sharply toward those aged 85 and above, a population that tends to be underdiagnosed and underpenetrated by specialty cardiology. Building physician awareness and diagnostic infrastructure ahead of approval is the real work DKSH is being paid to do.
The single marker worth tracking is the regulatory submission timeline in South Korea, which runs one of the more rigorous and predictable review processes in the region. A Korean approval would validate the regional dossier strategy and likely accelerate payer negotiations in Taiwan and Singapore. If DKSH can clear Korea, the other three markets follow a different, faster logic entirely.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
